This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, H.-R. Articles by Malkhosyan, S. R. Search for Related Content PubMed PubMed Citation Articles by Li, H.-R. Articles by Malkhosyan, S. R.

Hypersensitivity of Tumor Cell Lines with Microsatellite Instability to DNA Double Strand Break Producing Chemotherapeutic Agent Bleomycin

The Burnham Institute, La Jolla, California

Genetic or epigenetic inactivation of DNA mismatch repair genes results in a strong mutator phenotype, known as the microsatellite mutator phenotype or microsatellite instability (MSI). This mutator phenotype causes mutations in genes responsible for the regulation of cell growth and survival/death and thus promotes the development and progression of tumors. In addition to such tumorigenic lesions, mutations in genes of other types of DNA repair, for example, DNA double-strand break (DNA DSB) repair, are found in tumor cells with MSI. We report here that the majority of MSI-positive tumor cell lines of different tissue origins (endometrial, ovarian, prostate, and colorectal carcinomas) are hypersensitive to bleomycin, a DNA DSB producing chemotherapeutic drug. We suggest that this hypersensitivity may be a result of inactivation of the DNA DSB repair activity by concomitant mutations of different DNA DSB repair genes. To provide experimental support to this hypothesis, we show that the subclones of the MSI-positive colorectal cancer cell line HCT-8 that bear heterozygous frameshift mutations in the DNA DSB repair gene DNA-PK_CS are more sensitive to a combined treatment with bleomycin and the DNA protein kinase inhibitor LY294002 than the original HCT-8 cells, which are wild type for this gene. These results may be useful in designing therapies for MSI-positive cancer.

This article has been cited by other articles:

				C. L. Plumb, U. Adamcic, S. Shahrzad, K. Minhas, S. A.I. Adham, and B. L. Coomber Modulation of the Tumor Suppressor Protein {alpha}-Catenin by Ischemic Microenvironment Am. J. Pathol., October 1, 2009; 175(4): 1662 - 1674. [Abstract] [Full Text] [PDF]

				E. Vilar, B. Mukherjee, R. Kuick, L. Raskin, D. E. Misek, J. M.G. Taylor, T. J. Giordano, S. M. Hanash, E. R. Fearon, G. Rennert, et al. Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway Clin. Cancer Res., April 15, 2009; 15(8): 2829 - 2839. [Abstract] [Full Text] [PDF]

				J. R. Hart, O. Glebov, R. J. Ernst, I. R. Kirsch, and J. K. Barton DNA mismatch-specific targeting and hypersensitivity of mismatch-repair-deficient cells to bulky rhodium(III) intercalators PNAS, October 17, 2006; 103(42): 15359 - 15363. [Abstract] [Full Text] [PDF]

				H. Grabsch, M. Dattani, L. Barker, N. Maughan, K. Maude, O. Hansen, H. E. Gabbert, P. Quirke, and W. Mueller Expression of DNA Double-Strand Break Repair Proteins ATM and BRCA1 Predicts Survival in Colorectal Cancer Clin. Cancer Res., March 1, 2006; 12(5): 1494 - 1500. [Abstract] [Full Text] [PDF]